Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-123338
Filing Date
2024-11-07
Accepted
2024-11-07 16:11:33
Documents
51
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q evok-20240930.htm   iXBRL 10-Q 1300162
2 EX-10.1 evok-ex10_1.htm EX-10.1 201345
3 EX-10.2 evok-ex10_2.htm EX-10.2 181936
4 EX-10.3 evok-ex10_3.htm EX-10.3 195683
5 EX-10.4 evok-ex10_4.htm EX-10.4 58613
6 EX-31.1 evok-ex31_1.htm EX-31.1 13206
7 EX-31.2 evok-ex31_2.htm EX-31.2 13305
8 EX-32.1 evok-ex32_1.htm EX-32.1 8634
9 EX-32.2 evok-ex32_2.htm EX-32.2 8610
10 GRAPHIC img216185510_0.jpg GRAPHIC 39357
11 GRAPHIC img216185510_1.jpg GRAPHIC 55684
  Complete submission text file 0000950170-24-123338.txt   6163645

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT evok-20240930.xsd EX-101.SCH 840923
53 EXTRACTED XBRL INSTANCE DOCUMENT evok-20240930_htm.xml XML 733656
Mailing Address 420 STEVENS AVENUE SUITE 230 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 230 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

EIN.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36075 | Film No.: 241435782
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)